Literature DB >> 1538134

Saponin adjuvant enhancement of antigen-specific immune responses to an experimental HIV-1 vaccine.

J Y Wu1, B H Gardner, C I Murphy, J R Seals, C R Kensil, J Recchia, G A Beltz, G W Newman, M J Newman.   

Abstract

The adjuvant activity of a single highly purified saponin from the soap bark tree Quillaja saponaria was evaluated by using it as a component in an experimental vaccine containing rHIV-1 envelope protein (HIV-1 160D) adsorbed to alum. BALB/c mice immunized with experimental vaccine formulations containing the saponin adjuvant QS-21 produced significantly higher titers of antibodies than mice vaccinated with only the alum-adsorbed HIV-1 160D. Potent amnestic antibody responses to HIV-1 viral proteins were also induced. Ag-specific proliferative responses to recombinant proteins and to three variants of HIV-1 were significantly increased using QS-21 as an adjuvant. Alum-adsorbed HIV-1 160D failed to induce measurable proliferative responses to inactivated HIV-1 viruses, but group-specific proliferative responses were raised when the QS-21 adjuvant was used in the vaccine formulation. MHC class I restricted CTL specific for the immunodominant V-3 loop were induced but only when the QS-21 adjuvant was included in the vaccine formulation. The production of serine esterase by Ag-activated splenic mononuclear cells, indicating the maturation of precursor CTL, was used as a secondary measure of CTL activity, and this response was also increased. The specificity of antibody responses was not significantly broadened using QS-21; the adjuvant increased the immune recognition of epitopes throughout the HIV-1 glycoprotein 160. However, the specificity of the proliferation and serine esterase responses was broadened, suggesting that the QS-21 augmented cell-mediated immune responses specific for epitopes outside of the V-3 loop. Additionally, the QS-21 adjuvant appeared to induce recognition of weakly immunogenic epitopes that were not recognized using only alum-adsorbed HIV-1 160D. The ability of QS-21 to augment both antibody and cell-mediated immune responses suggests that this adjuvant could be a valuable component in subunit vaccines.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1538134

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  47 in total

1.  Prevention of rotavirus infections in vitro with aqueous extracts of Quillaja Saponaria Molina.

Authors:  Michael R Roner; Ka Ian Tam; Melody Kiesling-Barrager
Journal:  Future Med Chem       Date:  2010-07       Impact factor: 3.808

2.  Induction of single and dual cytotoxic T-lymphocyte responses to viral proteins in mice using recombinant hybrid Ty-virus-like particles.

Authors:  G T Layton; S J Harris; J Myhan; D West; F Gotch; M Hill-Perkins; J S Cole; N Meyers; S Woodrow; T J French; S E Adams; A J Kingsman
Journal:  Immunology       Date:  1996-02       Impact factor: 7.397

Review 3.  Optimal delivery of vaccines: clinical pharmacokinetic considerations.

Authors:  S Gizurarson
Journal:  Clin Pharmacokinet       Date:  1996-01       Impact factor: 6.447

4.  Recombinant parvovirus-like particles as an antigen carrier: a novel nonreplicative exogenous antigen to elicit protective antiviral cytotoxic T cells.

Authors:  C Sedlik; M Saron; J Sarraseca; I Casal; C Leclerc
Journal:  Proc Natl Acad Sci U S A       Date:  1997-07-08       Impact factor: 11.205

Review 5.  Drug delivery issues in vaccine development.

Authors:  M F Powell
Journal:  Pharm Res       Date:  1996-12       Impact factor: 4.200

6.  Functional analysis of 3-hydroxy-3-methylglutaryl coenzyme a reductase encoding genes in triterpene saponin-producing ginseng.

Authors:  Yu-Jin Kim; Ok Ran Lee; Ji Yeon Oh; Moon-Gi Jang; Deok-Chun Yang
Journal:  Plant Physiol       Date:  2014-02-25       Impact factor: 8.340

7.  Antibody and cytotoxic T-cell responses to soluble hepatitis B virus (HBV) S antigen in mice: implication for the pathogenesis of HBV-induced hepatitis.

Authors:  R Schirmbeck; K Melber; T Mertens; J Reimann
Journal:  J Virol       Date:  1994-03       Impact factor: 5.103

8.  Safety and immunogenicity of an AMA1 malaria vaccine in Malian children: results of a phase 1 randomized controlled trial.

Authors:  Mahamadou A Thera; Ogobara K Doumbo; Drissa Coulibaly; Matthew B Laurens; Abdoulaye K Kone; Ando B Guindo; Karim Traore; Mady Sissoko; Dapa A Diallo; Issa Diarra; Bourema Kouriba; Modibo Daou; Amagana Dolo; Mounirou Baby; Mahamadou S Sissoko; Issaka Sagara; Amadou Niangaly; Idrissa Traore; Ally Olotu; Olivier Godeaux; Amanda Leach; Marie-Claude Dubois; W Ripley Ballou; Joe Cohen; Darby Thompson; Tina Dube; Lorraine Soisson; Carter L Diggs; Shannon L Takala; Kirsten E Lyke; Brent House; David E Lanar; Sheetij Dutta; D Gray Heppner; Christopher V Plowe
Journal:  PLoS One       Date:  2010-02-04       Impact factor: 3.240

9.  Biotransformation of ginsenosides Rb1, Rg3 and Rh2 in rat gastrointestinal tracts.

Authors:  Tianxiu Qian; Zongwei Cai
Journal:  Chin Med       Date:  2010-05-26       Impact factor: 5.455

10.  Enhanced inhibitory effect of ultra-fine granules of red ginseng on LPS-induced cytokine expression in the monocyte-derived macrophage THP-1 cells.

Authors:  Hyoung-Cheol Lee; Radhakrishnan Vinodhkumar; Jang W Yoon; Seong-Kyu Park; Chang-Won Lee; Hong-Yeoul Kim
Journal:  Int J Mol Sci       Date:  2008-08-07       Impact factor: 6.208

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.